No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
TRU240719P75000
- 2.10
- -0.40-16.00%
15min DelayClose Jun 28 15:59 ET
2.40High2.05Low
2.40Open2.50Pre Close4 Volume19 Open Interest75.00Strike Price895.00Turnover29.59%IV1.70%PremiumJul 19, 2024Expiry Date0.84Intrinsic Value100Multiplier19DDays to Expiry1.26Extrinsic Value100Contract SizeAmericanOptions Type-0.5393Delta0.0794Gamma31.23Leverage Ratio-0.0470Theta-0.0189Rho-16.84Eff Leverage0.0678Vega
Intraday
- 5D
- Daily
News
Express News | TransUnion -Pursuant to Amendment,Extend Maturity Date Applicable to Revolving Credit Facility and 2023 Refinancing Term a-4 Loans to June 24, 2029
Express News | TransUnion -Units Entered Into Amendment No. 23 to Third Amended, Restated Credit Agreement, Dated as of Aug 9, 2017
Express News | TransUnion -on June 24, TransUnion Intermediate Holdings, Trans Union LLC Entered Into Amendment No. 23 to Third Amended, Restated Credit Deal
Car Affordability Affecting Auto Lending Market, Study Shows
As Consumers' Monthly Debt Loads Increase, Auto Lenders Must Adapt to Manage Risk, Increase Originations
RBC Capital Maintains TransUnion(TRU.US) With Buy Rating, Maintains Target Price $85
Comments
TransUnion's high P/S ratio, despite expected average revenue growth, suggests investors are more bullish than analysts. This could risk shareholders' investments and potential investors might pay an unnecessary premium if the P/S aligns with the growth outlook.
TransUnion's (NYSE:TRU) Shares May Have Run Too Fast Too SoonTransUnion's investments aren't yielding high returns despite increased capital investment, reflecting in modest stock returns over the past five years. It may not be an ideal choice for those seeking a multi-bagger stock.
CEO Chris Cartwright expressed that these strategic moves aim to maximize the company's operating model, enhance technology, reduce costs, and foster innovation as well as growth. According to him, this reflects the company's ongoing focus on creating shareholder value.
But these 10 moat stocks are undervalued according to Morningstar:
$International Flavors & Fragrances(IFF.US$
$Etsy Inc(ETSY.US$
$U.S. Bancorp(USB.US$
$Polaris(PII.US$
$Wells Fargo & Co(WFC.US$
$Comcast(CMCSA.US$
$Teradyne(TER.US$
$Equifax(EFX.US$
$Veeva Systems(VEEV.US$
$TransUnion(TRU.US$
Can you think of other cheap moat stocks?
$Berkshire Hathaway 13F(LIST2999.US$ $Berkshire Hathaway-A(BRK.A.US$ $Berkshire Hathaway-B(BRK.B.US$ $Apple(AAPL.US$ $Coca-Cola(KO.US$ $Meta Platforms(META.US$ $Microsoft(MSFT.US$ $Alphabet-C(GOOG.US$ $Alphabet-A(GOOGL.US$
$International Flavors & Fragrances(IFF.US$
$Etsy Inc(ETSY.US$
$U.S. Bancorp(USB.US$
$Polaris(PII.US$
$Wells Fargo & Co(WFC.US$
$Comcast(CMCSA.US$
$Teradyne(TER.US$
$Equifax(EFX.US$
$Veeva Systems(VEEV.US$
$TransUnion(TRU.US$
Can you think of other cheap moat stocks?
$Berkshire Hathaway 13F(LIST2999.US$ $Berkshire Hathaway-A(BRK.A.US$ $Berkshire Hathaway-B(BRK.B.US$ $Apple(AAPL.US$ $Coca-Cola(KO.US$ $Meta Platforms(META.US$ $Microsoft(MSFT.US$ $Alphabet-C(GOOG.US$ $Alphabet-A(GOOGL.US$
6
1
Gainers:
In reaction to earnings/guidance:
$Liberty Energy(LBRT.US$ +11.6%, $F5 Inc(FFIV.US$ +6.9%, $Encore Wire(WIRE.US$ + 5.6%, $Archer Daniels Midland(ADM.US$ +5.5%, $Bank of N.T Butterfield & Son(NTB.US$ +5%, $Albany International(AIN.US$ +5%, $3M(MMM.US$ +4.0%,
Other news:
$Shell Midstream(SHLX.US$ +10% (Shell USA to acquire all units in SHLX held by public at $15.85/unit total value $1.96 bln)
$BridgeBio Pharma(BBIO.US$...
In reaction to earnings/guidance:
$Liberty Energy(LBRT.US$ +11.6%, $F5 Inc(FFIV.US$ +6.9%, $Encore Wire(WIRE.US$ + 5.6%, $Archer Daniels Midland(ADM.US$ +5.5%, $Bank of N.T Butterfield & Son(NTB.US$ +5%, $Albany International(AIN.US$ +5%, $3M(MMM.US$ +4.0%,
Other news:
$Shell Midstream(SHLX.US$ +10% (Shell USA to acquire all units in SHLX held by public at $15.85/unit total value $1.96 bln)
$BridgeBio Pharma(BBIO.US$...
13
3
Read more